Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis

A global phase 3 trial (NCT06456580) evaluating telitacicept in generalized myasthenia gravis (gMG) is underway, building on prior data demonstrating clinically meaningful improvements in functional and strength-based outcomes.¹

At the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois, investigators outlined the design of the RemeMG study, a randomized, double-blind, placebo-controlled phase 3 trial assessing the efficacy and safety of telitacicept in adults with gMG.¹ The investigational therapy is a TACI-Fc fusion protein that targets both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), 2 cytokines central to B-cell maturation and survival. By inhibiting these pathways, telitacicept is designed to reduce the production of pathogenic autoantibodies that drive disease activity in gMG.²

Led by George Li, MD, a neurologist at MEDSOL Clinical Research Center, and colleagues, the RemeMG trial will enroll approximately 180 adult patients with acetylcholine receptor (AChR)– or muscle-specific tyrosine kinase (MuSK)–positive gMG who have had an inadequate response to standard-of-care therapies.¹ Eligible participants must have Myasthenia Gravis Foundation of America (MGFA) Class II–IV disease, a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 6, and a Quantitative Myasthenia Gravis (QMG) score of at least 8, reflecting a population with moderate to severe functional impairment.²

Following a screening period of up to 4 weeks, participants will be randomized 1:1 to receive weekly subcutaneous telitacicept or placebo during a 24-week double-blind treatment phase. The primary endpoint is the mean change from baseline in MG-ADL score at week 24, with secondary and exploratory endpoints including changes in QMG, as well as pharmacokinetic and pharmacodynamic measures. Patients who complete the blinded phase will enter a 48-week open-label extension, allowing for longer-term evaluation of treatment durability and safety.

The design of RemeMG is informed by previously reported phase 3 data that demonstrated strong efficacy signals for telitacicept. In a randomized, double-blind study conducted in China (NCT05737160), patients treated with telitacicept showed significant improvements across multiple clinical endpoints compared with placebo. At week 24, the mean change in MG-ADL score was –5.74 in the telitacicept group compared with –0.91 in the placebo group, indicating a substantial reduction in disease burden.³

READ MORE: Phase 3 EPIC Trial to Evaluate NRTX-1001 Cell Therapy in Drug-Resistant Mesial Temporal Lobe Epilepsy

Responder analyses further supported these findings, with 98.1% of telitacicept-treated patients achieving at least a 3-point reduction in MG-ADL, compared with 12.0% in the placebo arm. Similarly, QMG scores improved by –8.66 with telitacicept versus –2.27 with placebo, and 87.0% of treated patients achieved at least a 5-point improvement compared with 16.0% of those receiving placebo. These improvements were observed early in treatment and were sustained through the 24-week evaluation period.

From a safety standpoint, telitacicept was generally well tolerated, with overall adverse event rates comparable to placebo and a lower incidence of infection-related adverse events reported in the treatment group (45.6% vs 59.6%). The safety profile, combined with the magnitude of clinical benefit, has supported continued development of the therapy in global populations.

Mechanistically, telitacicept offers a distinct approach compared with other therapies used in gMG. By simultaneously targeting BAFF and APRIL, the agent may influence both mature B cells and plasma cells, potentially providing broader suppression of autoantibody production than therapies targeting a single pathway.² This upstream modulation of humoral immunity may be particularly relevant in a disease where autoantibody-mediated disruption of neuromuscular transmission is central to pathophysiology.

As the treatment landscape for gMG continues to evolve with the introduction of FcRn inhibitors, complement inhibitors, and B-cell–directed therapies, the RemeMG study will help clarify the potential role of dual BAFF/APRIL inhibition. While prior findings are encouraging, results from this global phase 3 trial will be important in determining the consistency, durability, and safety of telitacicept across a broader patient population.

Click here for more AAN 2026 coverage.

REFERENCES
1. Li G, Habib A, Meinert L, et al. A phase three randomized, double-blind, placebo-controlled study with an open-label extension to evaluate telitacicept in patients with generalized myasthenia gravis (RemeMG). Presented at: 2026 American Academy of Neurology Annual Meeting; April 18–22, 2026; Chicago, IL.
2. ClinicalTrials.gov. Study to evaluate the efficacy and safety of telitacicept in generalized myasthenia gravis. Accessed April 20, 2026. https://clinicaltrials.gov/study/NCT06456580
3. Phase 3 clinical trial results of telitacicept in generalized myasthenia gravis presented at AAN 2025. News release. RemeGen. April 25, 2025. Accessed April 20, 2026. https://www.prnewswire.com/news-releases/remegen-announces-exciting-results-of-telitacicept-phase-3-clinical-trial-for-patients-with-generalized-myasthenia-gravis-302424073.html